WO2000002911A3 - INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) - Google Patents

INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) Download PDF

Info

Publication number
WO2000002911A3
WO2000002911A3 PCT/US1999/015592 US9915592W WO0002911A3 WO 2000002911 A3 WO2000002911 A3 WO 2000002911A3 US 9915592 W US9915592 W US 9915592W WO 0002911 A3 WO0002911 A3 WO 0002911A3
Authority
WO
WIPO (PCT)
Prior art keywords
hslon
app
protein
human
interaction
Prior art date
Application number
PCT/US1999/015592
Other languages
French (fr)
Other versions
WO2000002911A2 (en
Inventor
Krishnan Nandabalan
Meijia Yang
Vincent Peter Schulz
Original Assignee
Curagen Corp
Krishnan Nandabalan
Meijia Yang
Vincent Peter Schulz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Krishnan Nandabalan, Meijia Yang, Vincent Peter Schulz filed Critical Curagen Corp
Priority to EP99932376A priority Critical patent/EP1095154A2/en
Priority to JP2000559140A priority patent/JP2002521004A/en
Priority to AU48693/99A priority patent/AU4869399A/en
Priority to CA002332625A priority patent/CA2332625A1/en
Publication of WO2000002911A2 publication Critical patent/WO2000002911A2/en
Publication of WO2000002911A3 publication Critical patent/WO2000002911A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention discloses an interaction between β-APP and HsLON and the formation of a β-APP:HsLON complex, or of the derivatives, fragments, analogs and homologs thereof, that were identified using a modified, improved yeast two hybrid assay system. Methodologies of screening these aforementioned complexes for efficacy in treating and/or preventing various diseases and disorders, particularly neurodegenerative disease, cardiomyopathy, diabetes, hearing loss, male infertility, mitochondrial DNA mutation associated disorders and the like, are also disclosed herein.
PCT/US1999/015592 1998-07-10 1999-07-08 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) WO2000002911A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99932376A EP1095154A2 (en) 1998-07-10 1999-07-08 Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon)
JP2000559140A JP2002521004A (en) 1998-07-10 1999-07-08 Interaction of human β-amidoid precursor protein (β-APP) with human LON protease-like protein (HsLON)
AU48693/99A AU4869399A (en) 1998-07-10 1999-07-08 Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon)
CA002332625A CA2332625A1 (en) 1998-07-10 1999-07-08 Interaction of human beta amyloid precursor protein (.beta.-app) with human lon-protease like protein (hslon)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11334898A 1998-07-10 1998-07-10
US09/113,348 1998-07-10

Publications (2)

Publication Number Publication Date
WO2000002911A2 WO2000002911A2 (en) 2000-01-20
WO2000002911A3 true WO2000002911A3 (en) 2001-01-18

Family

ID=22348923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015592 WO2000002911A2 (en) 1998-07-10 1999-07-08 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON)

Country Status (5)

Country Link
EP (1) EP1095154A2 (en)
JP (1) JP2002521004A (en)
AU (1) AU4869399A (en)
CA (1) CA2332625A1 (en)
WO (1) WO2000002911A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379620B1 (en) 1998-11-16 2002-04-30 Barry M. Tydings Assaying device and method for in field urinalysis
EP1305427A1 (en) * 2000-03-24 2003-05-02 Millennium Pharmaceuticals, Inc. 19053, an atpase-like molecule and uses thereof
CN1315402A (en) * 2000-03-28 2001-10-03 上海博德基因开发有限公司 Polypeptide-human amyloid precursor protein bindin 14 and polynucleotide for coding it
CN1315439A (en) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 Polypeptide-human amyloid precursor protein bindin 9 and polynucleotide for coding it
CN1323833A (en) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 New polypeptide-human amyloid precursor protein binding protein 51 and polynucleotides for coding same
DK1456380T3 (en) 2001-11-02 2012-07-30 Giuliani Int Ltd SMAD7 inhibitors for the treatment of CNS diseases
US6805838B2 (en) 2002-03-04 2004-10-19 Barry M. Tydings Assaying device and method for in field urinalysis
JP4421900B2 (en) * 2002-04-09 2010-02-24 ザ スクリップス リサーチ インスティテュート Motif-grafted hybrid polypeptide and use thereof
US7771952B2 (en) 2002-06-26 2010-08-10 Abott Laboratories Modulators and modulation of the interaction between RGM and Neogenin
CA2500831A1 (en) 2002-10-03 2004-04-15 Eric Hollander Treatment of autism and similar disorders
DE602004020855D1 (en) 2003-11-20 2009-06-10 Hoffmann La Roche Specific markers for metabolic syndromes
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011083147A1 (en) 2010-01-08 2011-07-14 Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
WO2011131626A1 (en) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
NZ625403A (en) 2012-01-27 2016-03-31 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20220133808A1 (en) * 2019-02-01 2022-05-05 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276723A2 (en) * 1987-01-30 1988-08-03 Bayer Ag Precursor protein of APC polypeptide, DNA coding therefor and diagnostic use of the DNA and protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276723A2 (en) * 1987-01-30 1988-08-03 Bayer Ag Precursor protein of APC polypeptide, DNA coding therefor and diagnostic use of the DNA and protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMERIK AYU ET AL: "Cloning and sequence analysis of cDNA for a human homolog of eubacterial ATP-dependent Lon proteases.", FEBS LETTERS, (1994 FEB 28) 340 (1-2) 25-8., XP002127967 *
FU G K ET AL: "The human LON protease binds to mitochondrial promoters in a single-stranded, site-specific, strand-specific manner.", BIOCHEMISTRY, (1998 FEB 17) 37 (7) 1905-9., XP002127966 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof

Also Published As

Publication number Publication date
AU4869399A (en) 2000-02-01
WO2000002911A2 (en) 2000-01-20
CA2332625A1 (en) 2000-01-20
JP2002521004A (en) 2002-07-16
EP1095154A2 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
WO2000002911A3 (en) INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON)
WO1999015657A3 (en) 53bp2 complexes
HUP9802212A2 (en) Recombinant anti-cd4 antibodies for human therapy
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2002046237A3 (en) Humanized antibodies that recognize beta amyloid peptide
CA2096911A1 (en) Amyloid precursor protein protease
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2000078344A8 (en) Prion protein peptides and uses thereof
WO2004110472A3 (en) Fusion proteins
AU2560599A (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
CA2222453A1 (en) Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
AU1679795A (en) Anti-fungal methods and materials
AU5596998A (en) Pyk2 related products and methods
TR199600116A2 (en) An a having a delta-5.7 sterol, delta-7 reductase activity, delta 7-red protein. DNA sequence coding, production process, transformed yeast type, uses for the transplanted protein.
WO2002032286A3 (en) Protein-protein interactions in neurodegenerative diseases
EP0897002A3 (en) U62317, a protein having a JNK-binding domain
WO1999025829A3 (en) Cdk2 protein and cdk2 protein complexes
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
HK1038510A1 (en) Use of neurotrophic factor stimulators for the treamtent of ophthalmic neurodegenerative diseases.
WO2001019851A3 (en) Opaminergic neuronal survival-promoting factors and uses thereof
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
EP0874050A3 (en) Integrin ligand ITGL-TSP
WO1999041376A8 (en) Retinoblastoma protein complexes and retinoblastoma interacting proteins
AU6042198A (en) Lage-1 tumor associated nucleic acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2332625

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 559140

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999932376

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 48693/99

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09743484

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999932376

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999932376

Country of ref document: EP